Sign in
CompletedNo phase

Ulinastatin Treatment Reduces the Incidence of Sepsis-associated Encephalopathy

Key facts

Who runs it
Shusheng Li
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
2,734 people enrolled
Started
1 Jan 2019
Ended
30 Nov 2024
Type of study
Observational, 2 groups
Treatments tested
  • ulinastatin
Record updated
31 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • age ≥18 years
  • ICU stay ≥24 hours
  • ulfillment of the diagnostic criteria for sepsis according to the Sepsis-3 definition, which included:
  • (a) suspected or confirmed infection based on clinical evidence and/or positive microbiological findings
  • (b) Sequential Organ Failure Assessment (SOFA) score ≥2 points

Who cannot take part

  • cognitive impairment related to sedation
  • inability to communicate effectively due to visual, auditory, or language disorders
  • primary central nervous system diseases (e.g., cerebrovascular disease, central nervous system infection, autoimmune encephalitis, or epileptic seizures)
  • intolerance or allergy to benzodiazepines, or a history of myasthenia gravis, schizophrenia, or severe depressive disorder
  • pregnancy
  • metabolic encephalopathy (including hypoglycemia, diabetic ketoacidosis, hepatic encephalopathy, pulmonary encephalopathy, or uremic encephalopathy)
  • poisoning
  • skull fracture or intracranial injury

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study was conducted to explore the association between ulinastatin treatment and the incidence of sepsis-associated encephalopathy (SAE) in patients with sepsis. The study was divided into two phases: first, a multicenter retrospective observational cohort: to evaluate the correlation between ulinastatin treatment and the risk of SAE; second, a single center prospective observational cohort: to further explore the association between ulinastatin treatment and SAE.

The 2 groups in the trial

  • Ulinastatin Group

    Patients diagnosed with sepsis who received ulinastatin as part of routine clinical care. The use of ulinastatin was not assigned by study protocol but determined by treating physicians. Clinical outcomes, including the incidence of SAE, were assessed.

    Treatment: ulinastatin

  • Non-Ulinastatin Group

    Patients diagnosed with sepsis who did not receive ulinastatin treatment during hospitalization. Clinical outcomes, including the incidence of SAE, were recorded. No study-specific interventions were applied.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
31 July 2025